NHS WYICB - Optimising Diabetes Pathway Management Through Greater Data Utilisation (Data Platform & Architecture)

Description

West Yorkshire Integrated Care Board (ICB) are running an early market engagement exercise to identify suppliers who may be interested in working in partnership to optimise management of the West Yorkshire diabetes pathway through the greater use of data. Lot 1: West Yorkshire Integrated Care Board (ICB) are running an early market engagement exercise to identify suppliers who may be interested in working in partnership to optimise management of the West Yorkshire diabetes pathway through the greater use of data. A Technology Appraisal (TA943) published by the National Institute for Clinical Excellence (NICE) in December 2023 recommended the use of hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. In partnership with the NHS England Diabetes Programme, a 5 year implementation strategy has been agreed for rolling out this technology across all target patient groups and across all ICBs within England. The roll-out of hybrid closed loop technologies brings with it increased flows of data within the system from the providers of such technologies, additional national clinical reporting requirements, and additional complexity in ensuring effective management of patients and the technologies they use. Currently, sharing, management, usage, and integration into national clinical data requirements is both challenging and disparate, relying on many systems (including clinical systems and those provided by technology suppliers) which don’t interface with one another. This challenge, and the scale of the data requirements, will only continue increasing as the 5 year implementation strategy progresses and the target population is widened. West Yorkshire ICB are keen to be at the forefront of this challenge and have an appetite to develop a data architecture and platform capable of utilising these disparate data sets to provide an end-end, data and insight-led view of the diabetes pathway. By harnessing the benefits which hybrid closed loop technologies have the potential to offer through greater data utilisation and insights, it’s intended this approach will deliver both clinical and operational improvements and requirements. This includes meeting national operating requirements, improvements in the local implementation of pathways, and unlocking efficiencies, but importantly, the potential to deliver improved care for people with diabetes through pathway optimisation. At this stage of the project, West Yorkshire ICB would like to engage with suppliers who would be interested in working in partnership to initially scope the current data provision, gaps, and insight needs, with a view to subsequently developing and implementing an appropriate data platform. Suppliers could include those interested in developing a bespoke platform, or those with their own existing data platform offering. For the avoidance of doubt, this notice is for early market engagement, and does not formally begin a procurement process or represent a commitment by West Yorkshire ICB to undertake an associated procurement process in the future. More information NICE Technology Appraisal TA943 Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes: https://www.nice.org.uk/guidance/ta943 NHS England Hybrid closed loop technologies 5-year implementation strategy: https://www.england.nhs.uk/long-read/hybrid-closed-loop-technologies-5-year-implementation-strategy/ Additional information: If you would like to express an interest in this opportunity, please submit your response by registering on https://nhswyicb.ukp.app.jaggaer.com reference PQQ_59. Once registered, potential suppliers will be able to complete and upload their submission. NHS WYICB reserve the right to pull this process.